Log in to your Inderes Free account to see all free content on this page.
Fluicell
13.50 SEK
-3.57 %
Less than 1K followers
FLUI
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Fluicell
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 2.5 | 4.6 | 2.6 | 3.3 | 3.3 | 1.9 | 6.0 |
| growth-% | 86.3 % | -43.9 % | 24.9 % | 2.8 % | -44.3 % | 222.7 % | |
| EBITDA | -18.2 | -16.4 | -21.1 | -21.0 | -26.3 | -15.4 | -8.0 |
| EBIT | -18.7 | -17.0 | -21.7 | -21.7 | -26.9 | -15.8 | -8.4 |
| Profit before taxes | -18.6 | -17.6 | -21.7 | -21.6 | -26.6 | -15.5 | -8.3 |
| Net income | -18.6 | -17.6 | -21.7 | -21.6 | -26.6 | -15.5 | -8.3 |
| EPS | -181.40 | -111.83 | -118.62 | -71.63 | -79.77 | -10.50 | -6.07 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -729.9 % | -354.3 % | -811.2 % | -646.5 % | -786.5 % | -828.0 % | -133.7 % |
| EBIT-% | -750.9 % | -367.3 % | -833.8 % | -668.6 % | -804.8 % | -851.6 % | -139.9 % |
| ROE | -182.2 % | -90.2 % | -113.5 % | -92.2 % | -6,174.4 % | -80.7 % | -76.4 % |
| ROI | -93.5 % | -70.8 % | -80.4 % | -68.0 % | -284.3 % | -60.8 % | -45.1 % |
Login required
This content is only available for logged in users